CLAIMS:

1. Use of a composition in the manufacture of a medicament for the treatment of a disease or a condition selected from hemorrhage, hypovolemia, burn, acute liver failure, liver dysfunction, hypoalbuminemia, adult respiratory distress syndrome, cirrhosis, neonatal hemolytic disease, cardiopulmonary bypass surgery, nephrosis, cancer, hepatorenal syndrome, sepsis, organ perfusion, or organ reperfusion in a subject, wherein the composition inhibits or reduces epithelial-mesenchymal transition (EMT), and contains:

(a) albumin;(b) an anti-EMT agent; and

(c) no pro-EMT agent or a low concentration of pro-EMT agent; and/or

a content of pro-EMT agent and anti-EMT agent in a ratio of pro-EMT agent : anti-EMT agent that is from 7:3 to 0:10;

wherein:

- the pro-EMT agent is octanoic acid, octanoate salt or a combination thereof;
- the anti-EMT agent is a C9-C14 fatty acid, a salt of C9-C14 fatty acid, a monoglyceride of C9-C14 fatty acid, a diglyceride of C9-C14 fatty acid, a triglyceride of C9-C14 fatty acid, or a combination thereof; and
- said low concentration of pro-EMT agent is less than 0.08 millimole per gram of albumin;
- with the proviso that, when the pro-EMT agent and the anti-EMT agent are fatty acids, they are distinct fatty acids or they are part of a diglyceride or a triglyceride.

2. The use of claim 1, wherein the low concentration of pro-EMT agent is 0.04 millimole per gram of albumin or less.

3. The use of claim 1, wherein the low concentration of pro-EMT agent is 0.007% (w/w) or less.

4. The use of claim 1, wherein the ratio of pro-EMT agent : anti-EMT agent is from 5:5 to 0:10.

5. The use of any one of claims 1 to 4, wherein the anti-EMT agent is a C9-C12 fatty acid, a salt of C9-C12 fatty acid, a monoglyceride of C9-C12 fatty acid, a diglyceride of C9-C12 fatty acid, a triglyceride of C9-C12 fatty acid, or a combination thereof.

6. The use of claim 5, wherein the anti-EMT agent is a C10-C12 fatty acid, a salt of C10-C12 fatty acid, a monoglyceride of C10-C12 fatty acid, a diglyceride of C10-C12 fatty acid, a triglyceride of C10-C12 fatty acid, or a combination thereof.

7. The use of claim 6, wherein the anti-EMT agent is a C10 fatty acid, a salt of C10 fatty acid, or a combination thereof.

8. The use of any one of claims 1 to 7, wherein said composition is an aqueous albumin preparation comprising from 1% to 40% (w/v) of albumin.

9. The use of any one of claims 1 to 8, wherein the salt is a salt of sodium, potassium, lithium, ammonium, calcium, magnesium, manganese, zinc, iron, copper, or a combination thereof.

10. The use of claim 9, wherein the salt is a salt of sodium.

11. The use of any one of claims 1 to 10, wherein the composition further comprises a pharmaceutically active agent.

12. The use of claim 11, wherein said active agent is an anticancer drug, and the medicament is for treating cancer.

13. The use of claim 12, wherein the anticancer drug is a taxane.

14. The use of claim 13, wherein taxane is paclitaxel or docetaxel.

15. The use of any one of claims 1 to 11, wherein the disease or condition is hemorrhage, hypovolemia, burn, or hypoalbuminemia.

16. Use of a composition in the manufacture of a medicament for inhibiting or reducing epithelial-mesenchymal transition (EMT) in a subject suffering from hemorrhage, hypovolemia, burn, acute liver failure, liver dysfunction, hypoalbuminemia, adult respiratory distress syndrome, cirrhosis, neonatal hemolytic disease, cardiopulmonary bypass surgery, nephrosis, cancer, hepatorenal syndrome, sepsis, organ perfusion, organ reperfusion, scar formation, psoriasis or eczema, wherein the composition comprises:

(a) an anti-EMT agent is a C9-C14 fatty acid, a salt of C9-C14 fatty acid, a monoglyceride of C9-C14 fatty acid, a diglyceride of C9-C14 fatty acid, a triglyceride of C9-C14 fatty acid, or a combination thereof; and

(b) no pro-EMT agent or a low concentration of pro-EMT agent; and/or

- a content of pro-EMT agent and anti-EMT agent in a ratio of pro-EMT agent : anti-EMT agent that is from 7:3 to 0:10;

wherein:

- the pro-EMT agent is octanoic acid, octanoate salt or a combination thereof;
- the anti-EMT agent is a C9-C14 fatty acid, a salt of C9-C14 fatty acid, a monoglyceride of C9-C14 fatty acid, a diglyceride of C9-C14 fatty acid, a triglyceride of C9-C14 fatty acid, or a combination thereof; and
- said low concentration of pro-EMT agent is less than 0.02 M;
- with the proviso that, when the pro-EMT agent and the anti-EMT agent are fatty acids, they are distinct fatty acids or they are part of a diglyceride or a triglyceride.

17. The use of claim 16, wherein the low concentration of pro-EMT agent is 0.01 M or less.

18. The use of claim 16, wherein the low concentration of pro-EMT agent is 0.001 M or less.

19. The use of claim 16, wherein the ratio of pro-EMT agent : anti-EMT agent is from 5:5 to 0:10.

20. The use of claim 19, wherein the ratio of pro-EMT agent : anti-EMT agent is 0:10.

21. The use of any one of claims 16 to 20, wherein the anti-EMT agent is a C9-C12 fatty acid, a salt of C9-C12 fatty acid, a monoglyceride of C9-C12 fatty acid, a diglyceride of C9-C12 fatty acid, a triglyceride of C9-C12 fatty acid, or a combination thereof.

22. The use of claim 21, wherein the anti-EMT agent is a C10-C12 fatty acid, a salt of C10-C12 fatty acid, a monoglyceride of C10-C12 fatty acid, a diglyceride of C10-C12 fatty acid, a triglyceride of C10-C12 fatty acid, or a combination thereof.

23. The use of claim 22, wherein the anti-EMT agent is a C10 fatty acid, a salt of C10 fatty acid, a monoglyceride of C10 fatty acid, a diglyceride of C10 fatty acid, a triglyceride of C10 fatty acid, or a combination thereof.

24. The use of any one of claims 16 to 23, wherein the salt is a salt of sodium, potassium, lithium, ammonium, calcium, magnesium, manganese, zinc, iron, copper, or a combination thereof.

25. The use of claim 24, wherein the salt is a salt of sodium.

26. The use of any one of claims 16 to 25, wherein the composition further comprises a pharmaceutically active agent.

27. The use of claim 26, wherein said active agent is an anticancer drug, and the medicament is for treating cancer.

28. The use of claim 27, wherein the anticancer drug is a taxane.

29. The use of claim 28, wherein taxane is paclitaxel or docetaxel.

30. The use of any one of claims 16 to 26, wherein the subject suffers from hemorrhage, hypovolemia, burn, or hypoalbuminemia.

31. The use of any one of claims 16 to 26, wherein the total concentration of pro-EMT agent and anti-EMT agent is between 5 mg/kg to 300 mg/kg of the subject per dose for oral or topical administration.

32. The use of claim 31, wherein said total concentration is between 10 mg/kg to 100 mg/kg per dose.

33. The use of any one of claims 16 to 26, wherein said total concentration is between 0.5 mg/kg to 100 mg/kg of the subject per dose for intravenous, intraperitoneal, rectal, intramuscular or subcutaneous administration.

34. The use of claim 33, wherein said total concentration is between 0.5 mg/kg to 4 mg/kg per dose.

35. The use of any one of claims 16-26, 31 and 34, wherein said composition is to be administered topically, and the medicament is for treating burn, scar, psoriasis or eczema, or for preventing scar formation.